Psychiatry and Clinical Psychopharmacology
March 30, 2026
Kenji Hashimoto, Feyza Arıcıoğlu, Mesut Çetin
Major depressive disorder remains a leading cause of disability worldwide, and current antidepressants are limited by delayed onset and incomplete response. Building on advances driven by ketamine research, renewed interest has focused on classical serotonergic psychedelics—particularly psilocybin, N,N-dimethyltryptamine (DMT), 5-methoxy-DMT, and lysergic acid diethylamide (LSD)—which, under...
PsyArXiv
March 28, 2026
David W. Lawrence, Ari Brouwer, Nicholas Fabiano et al.
preprint
Despite being induced by a transient pharmacological exposure, psychedelic experiences can catalyze enduring psychological transformation, presenting a central challenge for understanding the mechanism of action of psychedelic medicines. To address this challenge, the Allostatic Reset Model (ARM) of psychedelic action is proposed, which conceptualizes psychedelic therapeutic effects as a...
Psychopathology
March 27, 2026
Xiaoran Ding, Yaping Wu, Juan Yang et al.
1 citation
Ketamine has emerged as a promising rapid-acting antidepressant with distinct advantages for the treatment of treatment-resistant depression (TRD). Its therapeutic effects are mediated through multi-target modulation of the glutamatergic system. Unlike conventional antidepressants, ketamine exerts a markedly faster onset of action; however, its long-term safety profile and potential risk of...
Zenodo (CERN European Organization for Nuclear Research)
March 25, 2026
Stanley Everett Sambey
preprint
Psychedelic experiences are frequently described as producing a “psychological reset,”characterized by reduced rigidity of thought and disruption of maladaptive cognitive pat-terns. Existing models such as REBUS and the entropic brain hypothesis explain acutedestabilization but do not fully account for post-experience reconstruction. This paper pro-poses a two-stage mechanism: (1) constraint...
Translational Psychiatry
March 25, 2026
Gal Levi, Amnon Sintov, Joseph Zohar et al.
Ketamine holds promise for the treatment of post-traumatic stress disorder (PTSD), but challenges remain in delivery and sustained effects. This controlled study evaluates a novel intranasal formulation, employing AmyloLipid nanovesicles (ALN) to enhance ketamine’s therapeutic efficacy in a predator-scent stress (PSS) rat model of PTSD. A total of 130 rats underwent PSS or sham-PSS exposure,...
Scientific Journal of National Pedagogical Dragomanov University Series 15 Scientific and pedagogical problems of physical culture (physical culture and sports)
March 25, 2026
Nataliia Volovyk, Olena Pidvalna, Bohdan Antonevych
Yoga is a form of integrative health that combines a person's physical, mental, and spiritual health through body movements, conscious breathing, and meditation. Purpose of the article is to analyze and substantiate the role of yoga in shaping intrinsic motivation for a healthy lifestyle among higher education students. The study focuses on the psychological and physiological mechanisms that...
Frontiers in Cell and Developmental Biology
March 25, 2026
Mizuki Yamamoto, Haruka Hirakata, Koji Toda
5 citations
Major depressive disorder is a highly prevalent psychiatric condition that can affect individuals across the lifespan, yet its pathophysiology remains incompletely understood. Classical hypotheses, informed by preclinical and clinical studies, emphasized dysregulated monoaminergic neurotransmission and guided the development of widely prescribed antidepressants, including selective serotonin...
Mini-Reviews in Medicinal Chemistry
March 24, 2026
Shivaputra A Patil, Holly C Hunsberger
Psilocybin, chemically known as (4-phosphoryloxy-N, N-dimethyltryptamine, 4-PODMT), is derived from the psychoactive mushroom genus, Psilocybe. Of the four active metabolites, psilocin readily enters systemic circulation. The psychoactive effects of psilocin are thought to arise through partial agonist effects at the 5-HT2A receptor. Psychedelic drugs, including psilocybin, are having a...
International Journal of Molecular Sciences
March 20, 2026
Ana Zivanovic, Milos Mitic, Iva Lukic et al.
Major depressive disorder (MDD) is a highly prevalent psychiatric illness for which rapid-acting antidepressants such as ketamine provide only transient benefit. Because κ-opioid receptor (KOR) signaling contributes to stress-related dysphoria and impaired neuroplasticity, we examined whether KOR antagonism could prolong ketamine’s antidepressant-like effects in a mouse model of adolescent...
International Journal of Innovative Technologies in Social Science
March 19, 2026
Anna Komarczewska, Michał Kociński, Patryk Iglewski et al.
Depression and psychological distress are highly prevalent among patients with cancer and are associated with impaired quality of life, reduced treatment adherence, and poorer clinical outcomes. Standard pharmacological and psychosocial interventions often demonstrate limited efficacy or delayed onset of action in oncological and palliative settings. Psilocybin-assisted therapy has recently...